30 Aug 2020
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Author: admintech | Filed under: Press ReleaseEAST HANOVER, N.J., Aug. 30, 2020 /PRNewswire/ — Novartis today announced results from a post-hoc analysis of pooled data from the Phase III ORION-10 and -11 trials evaluating the individual responses of patients on low-density lipoprotein cholesterol (LDL-C) reduction with inclisiran, a…